HC Wainwright restated their buy rating on shares of Xeris Biopharma (NASDAQ:XERS - Free Report) in a research note issued to investors on Friday, MarketBeat reports. HC Wainwright currently has a $8.00 price target on the stock, up from their previous price target of $6.60. HC Wainwright also issued estimates for Xeris Biopharma's Q1 2025 earnings at ($0.08) EPS, Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at $0.01 EPS and FY2029 earnings at $0.78 EPS.
Several other research analysts have also commented on XERS. Piper Sandler lowered shares of Xeris Biopharma from an "overweight" rating to a "neutral" rating and set a $3.00 price target for the company. in a report on Monday, November 11th. Jefferies Financial Group reaffirmed a "buy" rating and set a $6.00 target price (up from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $5.92.
Read Our Latest Analysis on Xeris Biopharma
Xeris Biopharma Price Performance
XERS traded down $0.20 during trading hours on Friday, hitting $4.39. 4,430,709 shares of the stock were exchanged, compared to its average volume of 2,084,559. The stock has a market cap of $654.47 million, a price-to-earnings ratio of -9.76 and a beta of 2.32. The stock has a 50-day simple moving average of $3.59 and a 200-day simple moving average of $3.27. Xeris Biopharma has a 12 month low of $1.69 and a 12 month high of $4.68.
Institutional Investors Weigh In On Xeris Biopharma
Several hedge funds and other institutional investors have recently added to or reduced their stakes in XERS. China Universal Asset Management Co. Ltd. boosted its holdings in Xeris Biopharma by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 31,611 shares of the company's stock worth $107,000 after buying an additional 2,954 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Xeris Biopharma by 4.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 80,388 shares of the company's stock worth $273,000 after purchasing an additional 3,447 shares during the period. GPS Wealth Strategies Group LLC grew its position in Xeris Biopharma by 6.2% during the 4th quarter. GPS Wealth Strategies Group LLC now owns 66,925 shares of the company's stock worth $227,000 after purchasing an additional 3,900 shares in the last quarter. Janney Montgomery Scott LLC raised its position in Xeris Biopharma by 31.4% during the fourth quarter. Janney Montgomery Scott LLC now owns 23,000 shares of the company's stock valued at $78,000 after buying an additional 5,500 shares during the period. Finally, Prudential Financial Inc. lifted its holdings in shares of Xeris Biopharma by 23.4% during the 4th quarter. Prudential Financial Inc. now owns 36,945 shares of the company's stock valued at $125,000 after buying an additional 7,000 shares during the last quarter. Institutional investors own 42.75% of the company's stock.
Xeris Biopharma Company Profile
(
Get Free Report)
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Featured Articles
Before you consider Xeris Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xeris Biopharma wasn't on the list.
While Xeris Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
